CSL says first patient receives FDA-approved HEMGENIX in U.S.

CSL Behring announced that the first patient has received U.S. FDA approved HEMGENIXfor hemophilia B in the United States. HEMGENIX is the first and only gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes.